Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten.

ABSTRACT:

Background and objective

Aficamten, a small-molecule, selective cardiac myosin inhibitor, is under development for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Aficamten is primarily eliminated by hepatic metabolism with renal excretion playing a minor role. The objective of this investigation was to evaluate the pharmacokinetics (PK) of aficamten in moderate hepatic impairment or mild to moderate renal impairment to inform dosing recommendations in HCM patients with mild or moderate hepatic impairment or mild to moderate renal impairment.

Methods

The impact of hepatic impairment on the PK of single-dose aficamten 20 mg was evaluated in a phase 1 single-dose, open-label, parallel-group study, in healthy participants with moderate (n = 8) hepat

SUBMITTER: Xu D 

PROVIDER: S-EPMC11954688 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature